ランキングに戻る

Cellebrite DI Ltd. (CLBT)

割安
TechnologySoftware - InfrastructureIsrael

ファンダメンタル

66

株価

$11.13

時価総額

$2.83B

パート1 · 企業の価値

概要

Cellebrite DI Ltd. is an Israeli software company that sells digital investigation tools to law enforcement, prosecutors, defence and intelligence agencies, and to a smaller extent to corporate and private-sector investigators. Its products let an authorised investigator lawfully access a locked mobile phone, computer, cloud account or other digital source, extract the data, then review, analyse and share it in a form that can be used as evidence. The portfolio spans device access and extraction, analytics that connect evidence across many devices in one case, and case-management software that lets an agency share findings with prosecutors; it is complemented by lab-based advanced access services, training and certification. In fiscal 2025 the company reported total revenue of $475.7 million, and the filing states that more than 90% of revenue in 2023, 2024 and 2025 came from public-sector customers.

収益の仕組み

Cellebrite sells mostly through annual and multi-year subscription agreements rather than one-off licences. The filing splits revenue into four lines. Subscription services — cloud and hosted software billed over the term — were $330.8 million in fiscal 2025 and are recognised over the life of the subscription. Term licences — on-premise subscription licences — were $96.2 million and are recognised immediately at the point of sale. Together these two lines make up what the company calls subscription revenue, $427.0 million in 2025, up 21% on 2024. Professional services (advanced access work performed in Cellebrite's own labs, training and consulting) were $30.9 million, and other non-recurring revenue, which includes hardware, was $17.8 million. Two consequences matter for a reader: the company itself notes that a subscription model makes it hard to grow reported revenue quickly, because new business is spread across the contract term; and the upfront recognition of term licences can make individual quarters lumpy even when the underlying contract base is stable.

競争優位性(moat)

特許・ライセンス · 狭い

The difficult, repeatable thing Cellebrite does is re-engineer lawful access to devices whose makers keep hardening encryption and locking down operating systems. That is a research capability — proprietary methods, a large accumulated body of device and app knowledge, and the staff who maintain it — that very few firms can fund and sustain year after year. Around it sit softer but real frictions: evidence produced by the tool has to stand up in court, examiners are trained and certified on it, and the software is embedded in agency workflows and government purchasing vehicles, so switching is disruptive rather than merely inconvenient. The advantage is narrow rather than wide because competitors exist in the same niche, and because a phone maker closing a method can erase part of the capability at any time — the filing itself lists keeping pace with technological change and intense competition among its principal risks.

需要を左右する要因

ディフェンシブ

Demand is driven by the volume of digital evidence in ordinary casework rather than by the economic cycle: crimes are investigated, and phones and cloud accounts are part of nearly every case, whether the economy is expanding or contracting. Police, prosecution and intelligence budgets are among the last public expenses to be cut, which makes the underlying demand defensive. The qualification is timing rather than direction: the company's own risk factors point to government budgeting cycles, appropriations uncertainty, spending reductions and long sales cycles for larger transactions, so orders can slip between quarters or years even when the need has not changed.

主なリスク

  • Dependence on government and law-enforcement buyers — The company states that its business depends materially on the purchase, acceptance and use of its solutions by law enforcement and government agencies, and that more than 90% of revenue in 2023, 2024 and 2025 came from public-sector customers. Government contracts bring budgeting cycles, appropriations uncertainty, termination rights and the risk of spending reductions.
  • Keeping pace with technological change — Cellebrite lists its ability to keep pace with technological advances and evolving industry standards as a principal risk. Its access capabilities must be rebuilt continuously as device manufacturers and operating-system vendors change their security.
  • Renewal of subscriptions — Because the business is sold on annual and multi-year subscriptions, the filing identifies dependence on customers renewing those subscriptions as a specific risk; revenue is not secured beyond the contract term.
  • Errors, defects or bugs in the solutions — The company flags real or perceived errors, failures, defects or bugs in its digital investigation solutions as a risk. Output used as evidence is held to a higher standard than ordinary software output, so a defect can carry legal as well as commercial consequences.
  • Misuse of the solutions and reputational harm — Among its risk factors the company includes misuse of its solutions by customers and the negative publicity and reputational harm that can follow. Tools designed for lawful investigation can be deployed in ways that draw public and regulatory scrutiny.
  • Competition and consolidation — The filing lists intense competition and market consolidation among its risks, alongside dependence on technology licensed from third parties and on retaining sales and marketing personnel.
  • Artificial intelligence and currency exposure — The company names risks tied to implementing artificial intelligence in its products, and foreign-currency exposure: the filing notes that a substantial share of its expenses — around 32% — is denominated in Israeli shekels while revenue is largely in dollars. Geopolitical instability affecting its Israeli operations is also disclosed.

顧客集中度

The filing does not disclose a combined share for a set number of largest customers, so no figure is given here. What it does disclose is concentration by customer type: public-sector customers were more than 90% of revenue in 2023, 2024 and 2025, and U.S. federal government customers alone were approximately 16% of 2025 revenue. The practical reading is that the risk is not one large account walking away but a whole class of buyer — government agencies, and in particular the U.S. federal budget — moving together.

強気材料

Buyers argue that the amount of digital evidence per case keeps rising while agencies remain short of examiners, so the work Cellebrite automates is needed regardless of the economic cycle. They point to a revenue base that is now overwhelmingly subscription — $427.0 million of the $475.7 million reported for 2025, growing 21% — sold to public agencies that renew rather than shop around, and to the long shift of the installed base from one-off tools and hardware towards recurring software. They also argue that the company is widening from device access into analysis, case management and cloud and endpoint data, which raises the value of each agency relationship, and that the underlying research capability is very hard for a new entrant to replicate.

弱気材料

Sellers fear that a company taking more than 90% of its revenue from public agencies has no second leg to stand on when budgets tighten: the filing itself lists government budgeting cycles, appropriations uncertainty, termination rights and spending reductions, and U.S. federal customers alone were about 16% of 2025 revenue. They fear the technology side is a permanent arms race the company can lose — device makers keep hardening encryption, and the filing names keeping pace with technological change as a principal risk. They also point to the reputational and regulatory exposure the company discloses around customer misuse of its tools, to competition and consolidation in a narrow niche, and to the mechanics of the accounts: term licences recognised upfront can flatter or depress a quarter, and roughly 32% of expenses sit in shekels against dollar revenue, on top of the geopolitical risk of concentrating operations in Israel.

Generated on 2026年9月18日 with claude-haiku-4-5 — shared with all users

Direct competitors

Who this company fights with for the same customers

Generated on 2026年9月18日 with claude-haiku-4-5 — shared with all users

Magnet Forensics Inc. (merged with Grayshift, owned by Thoma Bravo)Not tracked

Sells the AXIOM investigation platform and the GrayKey mobile extraction tool to the same police forces, prosecutors and government agencies that buy Cellebrite's UFED and Inseyets.

Micro Systemation AB (MSAB)Not tracked

Its XRY extraction and XAMN analysis products cover the same mobile-forensics workflow for law enforcement in over 100 countries, and it bids for the same public-sector contracts.

Oxygen Forensics, Inc.Not tracked

Oxygen Forensic Detective extracts and analyses data from phones, cloud accounts and drones for the same investigative agencies, and is often the cheaper alternative in the same tenders.

Exterro, Inc.Not tracked

Through the former AccessData line (FTK) it sells digital forensics and e-discovery software to law enforcement and corporate investigation teams, the same buyers Cellebrite targets with its enterprise offering.

OpenText CorporationOTEX

Its EnCase Forensic and Endpoint Investigator products compete for the computer- and enterprise-side budget of the same police and corporate investigation units.

Nuix LimitedNXL

Nuix Neo processes and analyses seized digital evidence for police, regulators and corporate investigators, overlapping with Cellebrite's review and analytics tier rather than with device extraction.

貸借対照表と流動性

売上高

$514M

直近12か月(2026/6/30まで)

純利益

$59M

直近12か月(2026/6/30まで)

フリーキャッシュフロー

$125M

自己資本合計

$539M

負債合計

$23M

流動比率

1.62

利払い倍率

-

負債/EBITDA

0.30

一株当たり利益(EPS)

売上高と純利益

フリーキャッシュフロー

収益内訳

財務推移表

利益率の推移

負債の推移

負債の重さ

成長率グリッド

成長率 — 売上高

適正価値の推定

一般的なケース割安

適正価値

$19.86

現在株価

$11.13

安全マージン

+44.0%

適正価値レンジ

$12.91 - $26.81

使用した評価手法間のばらつきであり、統計的に較正された信頼区間ではありません。

推定方法

アナリストの目標株価:$15.36
ディスカウンテッド・キャッシュフロー(DCF):$35.26
利益倍率(P/E):$4.30
グレアムの成長公式:$11.84
収益力価値(EPV):$1.68
正当化されたP/B:$2.32
配当割引モデル(ゴードン):算出に必要なデータが不足しています
P/FFO(運用から生まれる資金):算出に必要なデータが不足しています
中間サイクル利益:算出に必要なデータが不足しています
売上高倍率:$10.01
アナリスト・コンセンサス:強い買い (14B / 1H / 0S)
直近の決算サプライズ:-2.57%

バリュエーション指標

P/E レシオ

48.96

ROE

12.4%

P/B レシオ

5.25

P/FCF

22.65

粗利益率

83.0%

ROIC

3.8%

収益性レーダー

価値創造(経済的モート)

ROIC

3.8%

WACC

10.3%

ROIC − WACC

-6.5 pp

ROICが資本コストを下回っています。投資した1ドルごとに企業は価値を破壊しています。

ファンダメンタル分析基準

合格(13)

  • Gross Margin 83.0%
  • P/FCF 22.65
  • Debt/Equity ratio
  • Positive Free Cash Flow
  • Current Ratio
  • Debt/EBITDA
  • ROE 11.9%
  • Revenue Growth 5Y 19.5%
  • Analyst Consensus 93% Buy
  • Earnings Surprise avg 6.8%
  • PEG Ratio 0.82
  • Earnings Quality (OCF/NI) 2.01
  • Net Margin Trend 16.5% vs -70.5%

不合格(6)

  • Price CAGR 1.48%
  • ROIC 3.8%
  • P/B Ratio 5.25
  • CapEx intensity
  • DCF valuation (Overvalued)
  • Piotroski F-Score 2/9

データなし(8)

  • EPS data insufficient
  • Dividend Payout NaN%
  • Operating Margin NaN%
  • Interest Coverage
  • Return on Tangible Assets
  • Low reliance on intangibles
  • Price below Graham Number
  • Share Dilution (missing shares data)

Piotroski F-スコア

2/9

重大な財務上の懸念

score
criteria

利益の質

2.01

高品質:利益はキャッシュに裏付けられている

株式希薄化

-

株式を買い戻している。株主に友好的

機関投資家の保有

この企業について機関投資家の報告はありません。

ガバナンス

経営陣

氏名役職年齢
Mr. David BarterChief Financial Officer53
Mr. Thomas E. HoganAdvisor66
Mr. Marcus JewellGlobal Chief Revenue Officer52
Mr. Shiven RamjiCEO & Director-
Mr. Christopher WadeChief Technology Officer41
Ms. Sigalit ShavitChief Information Officer57
Andrew KramerVP of Investor Relations & Treasury-
Ms. Holly B. Windham Esq., J.D.General Counsel & Chief Compliance Officer58
Mr. David Nicholas GeeChief Marketing Officer58
Ms. Zohar Tadmor-EilatChief People Officer53

パート2 · 株価と買い時

この部分は企業に価値があるかを判断するものではありません。ファンダメンタルズに納得したうえで、いつ買うかを選ぶためのものです。内容:テクニカル分析、ポテンシャル、過去のドローダウン、ガンマエクスポージャー。

Latest News

Recent headlines for CLBT, sourced from Markets Gazette.

No recent news for CLBT.